Inhibitors targeting AKT (MK2206), PI3K (GDC0941 and HS173), and mTORC1 (Rapamycin and Torin2) all reduced proliferation of PEL cell lines and induced apoptosis, cell death and cell cycle arrest. Here, AKT1 is linked to primary effusion lymphoma.